STOCK TITAN
  1. Home
  2. Sec-filings
  3. AMED
  4. [Form 4] Amedisys Inc Insider Trading Activity

Amedisys (AMED) Insider Award: 2,015 RSUs, Vesting 2026–2027

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Allyson Guidroz, the Chief Accounting Officer of Amedisys Inc. (AMED), was awarded 2,015 time-based restricted stock units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of the issuer's common stock and will vest 50% on August 6, 2026 and 50% on August 6, 2027, provided the reporting person remains continuously employed on those dates. The award is recorded at a $0 price in this filing.

Following the reported transaction the filing shows the reporting person beneficially owns 9,472 shares. The report references a plan statement dated June 30, 2025 and was signed on behalf of the reporting person by Jennifer Guckert Griffin on 08/08/2025.

Positive

  • 2,015 time-based RSUs awarded to Chief Accounting Officer (explicitly disclosed).
  • Vesting schedule specified: 50% on August 6, 2026 and 50% on August 6, 2027 (explicit condition of continued employment).
  • Beneficial ownership after transaction: 9,472 shares (explicitly shown in the filing).

Negative

  • None.

Insights

TL;DR: Chief Accounting Officer received 2,015 RSUs vesting 50% in 2026 and 2027; beneficial ownership shown as 9,472 shares.

The filing documents a routine equity compensation award rather than a market transaction. The award of 2,015 time-based RSUs creates a contingent right to receive common stock if vesting conditions are met. The filing explicitly states the vesting schedule and the plan statement date (June 30, 2025). No cash purchase or sales are reported, and the award is recorded at $0 in the Form 4.

TL;DR: The RSU grant is tied to continued employment with clear vesting dates; report filed by POA on 08/08/2025.

The disclosure identifies the reporting person and her role (Chief Accounting Officer), the exact award amount (2,015 RSUs) and precise vesting dates. The inclusion of the plan statement date (June 30, 2025) and a signature executed pursuant to a power of attorney are documented. Based on the filing content, this appears to be a standard equity grant disclosed under Section 16 reporting rules.

Insider Guidroz Allyson
Role Chief Accounting Officer
Type Security Shares Price Value
Grant/Award Common Stock 2,015 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 9,472 shares (Direct); Common Stock — 1.5 shares (Indirect, By 401(k) Plan)
Footnotes (1)
  1. The Issuer awarded the Reporting Person 2,015 time-based RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 50% on each of August 6, 2026 and August 6, 2027, provided that the Reporting Person remains continuously employed by the Issuer on each such date. The information in this report is based on a plan statement dated as of June 30, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Guidroz Allyson
(Last) (First) (Middle)
3854 AMERICAN WAY , SUITE A
(Street)
BATON ROUGE LA 70816
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AMEDISYS INC [ AMED ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Accounting Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/06/2025 A 2,015(1) A $0 9,472 D
Common Stock 1.5(2) I By 401(k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The Issuer awarded the Reporting Person 2,015 time-based RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 50% on each of August 6, 2026 and August 6, 2027, provided that the Reporting Person remains continuously employed by the Issuer on each such date.
2. The information in this report is based on a plan statement dated as of June 30, 2025.
Remarks:
/s/ Jennifer Guckert Griffin, pursuant to a power of attorney 08/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did AMED insider Allyson Guidroz receive on 08/06/2025?

The filing shows Allyson Guidroz was awarded 2,015 time-based RSUs on 08/06/2025.

When do the RSUs awarded to AMED's Chief Accounting Officer vest?

The RSUs vest 50% on August 6, 2026 and 50% on August 6, 2027, contingent on continued employment.

How many Amedisys (AMED) shares does the reporting person beneficially own after the award?

The Form 4 reports 9,472 shares beneficially owned following the reported transaction.

Was there a cash purchase price for the RSUs in the Form 4?

No purchase price is reported; the award is shown at $0 in the filing.

When was the Form 4 filed and who signed it?

The filing was signed on behalf of the reporting person by Jennifer Guckert Griffin on 08/08/2025 pursuant to a power of attorney.